


## ALK-IN-27 TFA

<b>Cat. No.:</b>	HY-156467A
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>23</sub> ClF <sub>4</sub> N <sub>6</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	566.94
<b>Target:</b>	Anaplastic lymphoma kinase (ALK)
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	-20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (176.39 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	1.7639 mL	8.8193 mL	17.6385 mL
		5 mM	0.3528 mL	1.7639 mL	3.5277 mL
	10 mM	0.1764 mL	0.8819 mL	1.7639 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.41 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.41 mM); Clear solution				

## BIOLOGICAL ACTIVITY

<b>Description</b>	ALK-IN-27 TFA is the TFA form of ALK-IN-27 (HY-156467). ALK-IN-27 (compound 1) is a potent ALK inhibitor. ALK-IN-27 shows antitumor activity. ALK-IN-27 has an IC <sub>50</sub> of 2.7 nM for Ba/F3 CLIP1-LTK cells <sup>[1]</sup> .
--------------------	--

## REFERENCES

[1]. Jennifer Anne Green, et al. Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacos-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine. WO2023196910A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA